Evidence map›Paper›PMID 31850686›Full record

ArticleJournal of the International AIDS Society2019

Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.

Tamara Elliott, Eduard J Sanders, Meg Doherty, Thumbi Ndung'u, Myron Cohen, Pragna Patel, Gus Cairns, Sarah E Rutstein, Jintanat Ananworanich, Colin Brown and 1 more

Open access · goldAbstract readScoping Review
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  13. Article
  14. A 43-year-old man with an indeterminate HIV test.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

Tamara ElliottImperial College London, London, United Kingdom.ORCID 0000-0001-8232-9413
Eduard J SandersKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Meg DohertyDepartment of HIV and Global Hepatitis Programme, WHO, Geneva, Switzerland.
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.
Myron CohenDepartment of Internal Medicine, Division of Infectious Diseases, UNC School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5917-9664
Pragna PatelDivision of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gus CairnsNAM Aidsmap, London, United Kingdom.
Sarah E RutsteinDepartment of Internal Medicine, Division of Infectious Diseases, UNC School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Jintanat AnanworanichU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID 0000-0003-1369-3224
Colin BrownNational Infection Service, Public Health England, London, United Kingdom.
Sarah FidlerImperial College London, London, United Kingdom.ORCID 0000-0003-1676-7583
University of North Carolina at Chapel Hill · USCenters for Disease Control and Prevention · USCentre for the AIDS Programme of Research in South Africa · ZAHenry M. Jackson Foundation · USImperial College Healthcare NHS Trust · GBKenya Medical Research Institute · KENIHR Imperial Biomedical Research Centre · GBRoyal Free London NHS Foundation Trust · GBWorld Health Organization · CH

Funding

Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmissionR01AI124968 · NIAID · UNIVERSITY OF WASHINGTON · PI GRAHAM, SUSAN MARIE, SANDERS, EDUARD · 2016 to 2019
$2.3M
NIAID NIH HHS R01 AI124968PEPFARWellcome Trust 107752/Z/15/ZWorld Health Organization 001
6 · The paper itself

Abstract

introductionKnowledge of HIV status relies on accurate HIV testing, and is the first step towards access to HIV treatment and prevention programmes. Globally, HIV-status unawareness represents a significant challenge for achieving zero new HIV infections and deaths. In order to enhance knowledge of HIV status, the World Health Organisation (WHO) recommends a testing strategy that includes the use of HIV-specific antibody point-of-care tests (POCT). These POCTs do not detect acute HIV infection, the stage of disease when viral load is highest but HIV antibodies are undetectable. Complicating things further, in the presence of antiretroviral therapy (ART) for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), other currently available testing technologies, such as viral load detection for diagnosis of acute HIV infection, may yield false-negative results. In this scoping review, we evaluate the evidence and discuss alternative HIV testing algorithms that may mitigate diagnostic dilemmas in the setting of increased utilization of ART for immediate treatment and prevention of HIV infection. DISCUSSION: Missed acute HIV infection prevents people living with HIV (PLHIV) from accessing early treatment, increases likelihood of onward transmission, and allows for inappropriate initiation or continuation of PrEP, which may result in HIV drug resistance. While immediate ART is recommended for all PLHIV, studies have shown that starting ART in the setting of acute HIV infection may result in a delayed or complete absence of development of HIV-specific antibodies, posing a diagnostic challenge that is particularly pertinent to resource-limited, high HIV burden settings where HIV-antibody POCTs are standard of care. Similarly, ART used as PrEP or PEP may supress HIV RNA viral load, complicating current HIV testing algorithms in resource-wealthy settings where viral detection is included. As rollout of PrEP continues, HIV testing algorithms may need to be modified.

conclusionsWith increasing use of PrEP and ART in acute infection we anticipate diagnostic challenges using currently available HIV testing strategies. Research and surveillance are needed to determine the most appropriate assays and optimal testing algorithms that are accurate, affordable and sustainable.

Indexed as

Anti-HIV AgentsHIV InfectionsHumansMalePost-Exposure ProphylaxisPre-Exposure ProphylaxisViral LoadAnti-HIV AgentsAcute HIV infectionHIV testing algorithmsimmediate antiretroviral therapyindeterminate HIV testpost-exposure prophylaxispre-exposure prophylaxis

Identifiers

PMID31850686
PMCPMC6918508
OpenAlexW2996596020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.